Published in Antimicrob Agents Chemother on April 01, 2005
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Inhibition of dengue virus by targeting viral NS4B protein. J Virol (2011) 1.31
Cell-based Assays to Identify Inhibitors of Viral Disease. Expert Opin Drug Discov (2008) 1.11
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob Agents Chemother (2009) 1.05
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening. Antimicrob Agents Chemother (2006) 1.02
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother (2014) 0.95
Cell viability assessment: toward content-rich platforms. Expert Opin Drug Discov (2010) 0.94
Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening. Curr Protoc Microbiol (2010) 0.94
Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles. J Virol (2012) 0.92
Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay. Virol J (2006) 0.86
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother (2011) 0.84
Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models. PLoS One (2013) 0.81
Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication. Antimicrob Agents Chemother (2008) 0.80
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus. PLoS One (2012) 0.80
New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov (2012) 0.76
Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob Agents Chemother (2014) 0.76
Antiviral drugs: New oral HCV drug shows promise. Nat Rev Drug Discov (2010) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science (2003) 7.91
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol (2001) 6.71
Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol (2001) 6.37
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 5.47
A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods (1994) 5.34
Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol (2001) 4.86
Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol (1997) 4.71
Subgenomic replicons of the flavivirus Kunjin: construction and applications. J Virol (1997) 3.92
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol (2003) 3.84
Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons. Proc Natl Acad Sci U S A (1989) 3.65
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol (1994) 3.51
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol (1995) 3.41
Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol (1993) 3.37
The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology (2001) 3.25
C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun (1995) 3.09
Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Commun (1994) 2.89
Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol (2003) 2.86
Construction and characterization of poliovirus subgenomic replicons. J Virol (1988) 2.69
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun (1993) 2.67
Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology (2002) 2.49
Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol (2001) 2.40
Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol (2003) 2.37
Novel cell culture systems for the hepatitis C virus. Antiviral Res (2001) 2.26
Characterization of an autonomous subgenomic pestivirus RNA replicon. J Virol (1998) 2.16
Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother (2003) 1.99
In vivo DNA expression of functional brome mosaic virus RNA replicons in Saccharomyces cerevisiae. J Virol (1997) 1.71
Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology (2002) 1.62
Replication studies using genotype 1a subgenomic hepatitis C virus replicons. J Virol (2003) 1.42
A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem (1996) 1.40
Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J Virol (2003) 1.36
Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol (2003) 1.33
The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proc Natl Acad Sci U S A (1995) 1.30
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem (2003) 1.30
Specific inhibition of bovine viral diarrhea virus replicase. J Virol (2003) 1.28
Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J Virol (2000) 0.99
Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal Biochem (2003) 0.94
Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus. J Virol (1997) 0.93
Genetic screen for monitoring hepatitis C virus NS3 serine protease activity. Antimicrob Agents Chemother (2003) 0.92
Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs (2001) 0.90
Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. J Gen Virol (1999) 0.88
Inducible model to study negative strand RNA synthesis and assembly of hepatitis C virus from a full-length cDNA clone. J Virol Methods (2001) 0.86
A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. J Virol Methods (1999) 0.84
In vivo assay for hepatitis C viral serine protease activity using a secreted protein. J Virol Methods (1998) 0.84
Hep3B human hepatoma cells support replication of the wild-type and a 5'-end deletion mutant GB virus B replicon. J Virol (2003) 0.81
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
The mammalian exosome mediates the efficient degradation of mRNAs that contain AU-rich elements. EMBO J (2002) 4.13
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
A role for small RNAs in DNA double-strand break repair. Cell (2012) 3.15
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol (2007) 2.59
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology (2012) 2.29
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
True versus reported waiting times for valvular aortic stenosis surgery. Can J Cardiol (2006) 2.21
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Significant improvement in short-term mortality in women undergoing coronary artery bypass surgery (1991 to 2004). J Am Coll Cardiol (2007) 2.11
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J (2003) 1.72
Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol (2006) 1.52
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol (2002) 1.47
Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46
Small intestinal hemolymphangioma with bleeding: a case report. World J Gastroenterol (2012) 1.45
Identifying priorities in methodological research using ICD-9-CM and ICD-10 administrative data: report from an international consortium. BMC Health Serv Res (2006) 1.45
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol (2011) 1.44
Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J (2007) 1.41
The mortality rate from anorexia nervosa. Int J Eat Disord (2005) 1.40
Trends in wait times for cardiac revascularization. Can J Cardiol (2011) 1.39
Percutaneous coronary intervention and 30-day mortality: the British Columbia PCI risk score. Catheter Cardiovasc Interv (2009) 1.37
Acanthamoeba keratitis: clinical characteristics and management. Ophthalmology (2006) 1.36
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci U S A (2004) 1.30
Specific inhibition of bovine viral diarrhea virus replicase. J Virol (2003) 1.28
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet (2008) 1.26
Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother (2004) 1.26
Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22
Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest (2006) 1.21
Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene (2005) 1.19
Outcome of mitral valve repair or replacement: a comparison by propensity score analysis. Circulation (2003) 1.19
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother (2012) 1.17
Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol (2006) 1.12
Human RIF1 encodes an anti-apoptotic factor required for DNA repair. Carcinogenesis (2009) 1.12
Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet (2012) 1.12
Evolution and expression analysis of the grape (Vitis vinifera L.) WRKY gene family. J Exp Bot (2014) 1.11
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother (2013) 1.11
Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Womens Health (Larchmt) (2013) 1.11
Replication-competent chimeric hepatitis C virus subgenomic replicons. Intervirology (2005) 1.10
Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother (2012) 1.09
The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol (2011) 1.08
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res (2012) 1.07
Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother (2012) 1.06
In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother (2011) 1.05
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice. Arthritis Rheum (2010) 1.03
Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J (2013) 1.02
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother (2012) 1.01
Multi-detector CT enterography with iso-osmotic mannitol as oral contrast for detecting small bowel disease. World J Gastroenterol (2005) 1.01
A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet (2005) 1.00
Genomic organization, phylogenetic comparison and differential expression of the SBP-box family genes in grape. PLoS One (2013) 1.00
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother (2004) 1.00
Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol (2012) 0.98
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut (2013) 0.98
Defining NOTCH3 target genes in ovarian cancer. Cancer Res (2012) 0.97
Revascularization use and survival outcomes after cardiac catheterization in British Columbia and Alberta. Can J Cardiol (2004) 0.97
Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol (2007) 0.96
Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol (2012) 0.96
Genome-wide identification and analysis of the TIFY gene family in grape. PLoS One (2012) 0.95
In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother (2002) 0.95
Characterizations of HCV NS5A replication complex inhibitors. Virology (2013) 0.95
Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion (2009) 0.94
Growth and performance of yttrium oxide as an ideal high-kappa gate dielectric for carbon-based electronics. Nano Lett (2010) 0.94